Scienture Holdings Inc

Análisis de la acción Scienture Holdings Inc (MEDS)

$1.165

-0.053 (-4.51%)Al cierre

Loading chart…
Máximo
1.240
Apertura
1.200
Precio medio ponderado por volumen
1.18
Volumen
114.44K
Capitalización
18.51M
Mínimo
1.130
Importe
134.84K
EV/EBITDA, TTM
0.00

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services.

Análisis de IA of Scienture Holdings Inc (MEDS)

Vender

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

Métricas de valoración

El PER previsto actual de Scienture Holdings Inc (MEDS) es 0.00, frente a su media de 5 años de 21.83.

PER previsto

Muy infravalorado
Media 5A P/E
21.83
P/E actual
0.00
Sobrevalorada
21.83
Infravalorada
21.83

EV/EBITDA previsto

Muy sobrevalorado
Media 5A EV/EBITDA
-0.01
EV/EBITDA actual
0.00
Sobrevalorada
-0.01
Infravalorada
-0.01

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
1.43
P/S actual
0.00
Sobrevalorada
1.43
Infravalorada
1.43

Cronología de eventos

2026-11-05 (ET)

10:00:00

DataMeds AI Signs MOU with Florida HMO

2026-11-03 (ET)

18:30:00

DataMeds AI Terminates Letter of Intent with Datavault AI

2026-11-02 (ET)

06:30:00

DataMeds AI Subsidiary Corexa Health Signs Drug Supply Agreement

2026-10-22 (ET)

08:30:00

Datavault AI Plans to Acquire 19.9% Stake in DataMEDS

08:00:00

DataMEDS Enters into Letter of Intent with Datavault AI

Noticias

Preguntas frecuentes sobre MEDS, respondidas por Alphio AI

DataMeds AI, Inc., formerly Wellgistics Health, Inc., is a holding company. It is engaged in health information technology (IT) that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The Company conducts its business through two wholly owned subsidiaries, Wood Sage, LLC and Wellgistics LLC, and two indirect subsidiaries, Alliance Pharma Solutions, LLC and Community Specialty Pharmacy, LLC. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows clinical services to be connected to its health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, prescription price transparency, and provide additional concierge services. It operates in the Healthcare sector (WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRI industry).

TRxADE Health Inc (MEDS) is not a good buy right now due to significant financial losses and poor technical indicators. The current price is $1.17, with a 5-day change of -39.32% and a year-to-date change of -66.90%. The RSI is at 9.228, indicating that the stock is extremely oversold, but this does not guarantee a rebound. The main risk is the company's negative net income, which reached -$18,363,225 in Q2 2026, reflecting ongoing financial instability.

Comunidad

Más ↗
Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar